Last $2.20 USD
Change Today -0.02 / -0.90%
Volume 10.1K
VRML On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

vermillion inc (VRML) Snapshot

Open
$2.17
Previous Close
$2.22
Day High
$2.29
Day Low
$2.17
52 Week High
03/4/14 - $3.83
52 Week Low
08/6/14 - $1.50
Market Cap
79.0M
Average Volume 10 Days
16.3K
EPS TTM
$-0.43
Shares Outstanding
35.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERMILLION INC (VRML)

Related News

No related news articles were found.

vermillion inc (VRML) Related Businessweek News

No Related Businessweek News Found

vermillion inc (VRML) Details

Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women’s health. The company’s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.

26 Employees
Last Reported Date: 03/31/14
Founded in 1993

vermillion inc (VRML) Top Compensated Officers

Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $184.0K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

vermillion inc (VRML) Key Developments

Vermillion, Inc. Appoints Holly B. Bauzon as Vice President of Sales and Managed Markets

Vermillion, Inc. has appointed Holly B. Bauzon as Vice President of Sales and Managed Markets. Ms. Bauzon has more than 20 years of healthcare experience, most recently with PerkinElmer, Inc., where she held the position of Director, Lab Services Sales and Managed Markets. Prior to her seven year tenure at PerkinElmer, Ms. Bauzon held commercial management and payer relations positions at PolyMedica Corporation, National Diabetic Pharmacies, Inc. and Byram Healthcare, Inc.

Vermillion, Inc. Appoints Dr. Judith K. Wolf as Chief Medical Officer, Effective September 15, 2014

Vermillion, Inc. appointed Dr. Judith K. Wolf to the new position of Chief Medical Officer, effective September 15, 2014. Dr. Wolf is a published and active professional in the field of gynecologic cancer. She currently serves as the Division Chief of Surgical Oncology and Vice Chair of the Department of Oncology Services at the Banner MD Anderson Cancer Center in Arizona.

Vermillion, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Cash for Operations Guidance for the Year 2014

Vermillion, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $324,000 against $323,000 a year ago. Loss from operations was $5,558,000 against $2,119,000 a year ago. Net loss was $5,555,000 against $2,117,000 a year ago. Basic and diluted net loss per share was $0.15 against $0.11 a year ago. The company used $3,800,000 in cash for operations in the second quarter of 2014. For the six months, the company reported total revenue of $629,000 against $651,000 a year ago. Loss from operations was $9,553,000 against $4,721,000 a year ago. Net loss was $9,542,000 against $4,688,000 a year ago. Basic and diluted net loss per share was $0.27 against $0.27 a year ago. The company expects to utilize $4.5 million to $5.5 million in cash for operations in the third quarter of 2014. The third quarter of 2014 is expected be high point for cash utilization before normalizing at a lower level beginning in the fourth quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRML:US $2.20 USD -0.02

VRML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arrayit Corp $0.14 USD -0.011
Health Discovery Corp $0.02 USD +0.0029
Imperial Innovations Group PLC 465.00 GBp +5.50
MDxHealth €4.02 EUR +0.182
Miraculins Inc C$0.27 CAD -0.01
View Industry Companies
 

Industry Analysis

VRML

Industry Average

Valuation VRML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.3x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERMILLION INC, please visit www.vermillion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.